Seven Eight Capital, LP Vertex Pharmaceuticals Inc Transaction History

Seven Eight Capital, LP

$1.05 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$392.81 - $485.53 $2.5 Million - $3.08 Million	6,352 New	6,352 $2.98 Million
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $11 Million - $13.2 Million	-32,168 Reduced 95.9%	1,376 $559,000
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $7.85 Million - $8.41 Million	23,206 Added 224.47%	33,544 $11.7 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $3.04 Million - $3.4 Million	9,661 Added 1427.03%	10,338 $3.64 Million
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $3.75 Million - $4.28 Million	-13,249 Reduced 95.14%	677 $213,000
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $3.03 Million - $3.41 Million	10,611 Added 320.09%	13,926 $4.02 Million
Q3 2022 Nov 10, 2022	BUY	$273.83 - $305.53 $907,746 - $1.01 Million	3,315 New	3,315 $960,000
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $1.54 Million - $1.94 Million	-8,676 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $1.57 Million - $1.76 Million	8,676 New	8,676 $1.57 Million
Q2 2021 Aug 13, 2021	SELL	$187.49 - $221.1 $601,655 - $709,509	-3,209 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$207.01 - $276.09 $664,295 - $885,972	3,209 New	3,209 $758,000
Q1 2020 May 14, 2020	SELL	$199.77 - $247.81 $1.05 Million - $1.3 Million	-5,239 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $10 Million - $13.5 Million	-60,200 Reduced 91.99%	5,239 $1.15 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $1.36 Million - $1.53 Million	8,167 Added 14.26%	65,439 $11.1 Million
Q2 2019 Aug 12, 2019	BUY	$164.61 - $190.37 $1.73 Million - $2 Million	10,500 Added 22.45%	57,272 $10.5 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $1.4 Million - $1.67 Million	8,572 Added 22.44%	46,772 $8.6 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $2.05 Million - $2.59 Million	13,500 Added 54.66%	38,200 $6.33 Million
Q3 2018 Oct 18, 2018	SELL	$167.73 - $192.74 $3.05 Million - $3.51 Million	-18,200 Reduced 42.42%	24,700 $4.76 Million
Q2 2018 Aug 07, 2018	SELL	$145.72 - $169.96 $1.37 Million - $1.6 Million	-9,400 Reduced 17.97%	42,900 $7.29 Million
Q1 2018 May 14, 2018	BUY	$151.6 - $177.13 $3.91 Million - $4.57 Million	25,800 Added 97.36%	52,300 $8.52 Million
Q4 2017 Feb 12, 2018	SELL	$137.28 - $155.55 $2.9 Million - $3.28 Million	-21,100 Reduced 44.33%	26,500 $3.97 Million
Q3 2017 Oct 16, 2017	BUY	$148.13 - $162.24 $5.57 Million - $6.1 Million	37,600 Added 376.0%	47,600 $7.24 Million
Q2 2017 Aug 10, 2017	BUY	N/A	10,000	10,000 $1.29 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.5 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.8 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.9 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.49 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.18 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Account